Key Advances in Targeted Radiotherapies at SNMMI24 by Actinium

Actinium Pharmaceuticals presented compelling data from their diverse clinical trials at SNMMI24:

Key among these was the completion of the Phase 1b trial of Actimab-A in combination with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (r/r AML).

Actimab-A, which targets the CD33 antigen via a monoclonal antibody linked to the alpha-emitting isotope Actinium-225, has shown promising results in enhancing patient outcomes both as a single agent and in combination with other therapies.

Additionally, significant findings from the Phase 3 SIERRA trial of Iomab-B were highlighted. This CD45 targeting ARC, using the Iodine-131 isotope, has been instrumental in conditioning r/r AML patients for potentially curative bone marrow transplants.

Achieving its primary endpoint of durable Complete Remission with high statistical significance, Iomab-B’s effectiveness, particularly for patients with TP53 mutations – who typically have a dismal prognosis – was underscored.